HealthTech BioActives (HTBA) has announced Miura Partners as its new majority shareholder, a move aligned with the company’s ongoing growth strategy across its four business areas: Functional Health, Pharmaceutical Active Ingredients (APIs), Taste Modulation, and Animal Nutrition.
HTBA successfully pursued a major international expansion and modernisation project over five years under its previous owner, The Riverside Company. Thanks to Miura’s commitment to innovative and sustainable development, HTBA begins its new chapter with an annual revenue of 80 million Euros, a figure up 66% since 2019, and with a 200-strong international workforce, which has doubled in that same time frame. Headquartered in Barcelona, with a subsidiary in Cincinnati, Ohio, today HTBA also operates a research, development, and production centre in Beniel (Murcia).
Said Alexandre Valls-Coma, Chief Executive Officer of HTBA: “The agreement of our new shareholder structure with Miura Partners is an important milestone for HTBA, reinforcing our position as a rising star in the health and nutrition industry. We remain fully focused on our mission of unlocking the power of nature through our proprietary processes and high-purity ingredients, with a genuine commitment to sustainability. Staying true to these principles has enabled us to enhance the health and well-being of both people and animals for over 40 years, and made us a global leader in the manufacturing and distribution of flavonoids and active forms of vitamin B12. Now, as we begin our partnership with Miura, we can’t wait to take our ambitious growth plans to the next level.” For more visit Miura Partners.
